Patients with rheumatoid arthritis who achieve LDA with a combination of tofacitinib plus methotrexate may consider withdrawing methotrexate without significant worsening of disease activity or unexpected safety issues.
Explore clinical research, expert reviews, and comment and opinion from The Lancet Rheumatology. A voice for rheumatology specialists worldwide
For the subgroup of patients with rheumatoid arthritis who require biological DMARDs, sustained DMARD-free remission does not seem attainable. In contrast, in patients with rheumatoid…
This study suggests that, compared with placebo, individuals with polymyalgia rheumatica receiving 4 mg baricitinib are less likely to need oral glucocorticoids to have low…
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy is approved to treat some types of relapsed B-cell lymphomas and leukaemias, and B-cell maturation antigen (BCMA)-targeted CAR…
Chimeric antigen receptor (CAR)-based therapies developed for the treatment of haematological malignancies have recently been repurposed to treat refractory systemic autoimmune diseases. In this Review…
As the world grapples with economic instability, political turmoil, and ongoing conflicts fuelling a global cost of living crisis, people with rheumatic and musculoskeletal (MSK)…
Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A…
Allogeneic HSCT might be a valuable treatment option for patients with refractory sJIA and sJIA-LD and should be considered for children with worsening oxygen dependence…
The first episode of a mini series on cell-based therapies in rheumatology, with Prof Rebecca Marsh and Grant Schulert discussing the use of allogeneic haematopoietic…
Edoardo Cipolletta and colleagues1 present compelling evidence that colchicine flare prophylaxis reduces cardiovascular event risk within 180 days of initiating urate-lowering therapy in patients with…
